The Influence of Physical Activity on Monocyte Phenotype on Circulating Platelet-Monocyte Complexes in Overweight/Obese Persons by Levitt, Michael M et al.
 International Journal of Exercise Science                                                             www.tacsm.org 
TACSM Abstract 
 
The Influence of Physical Activity and Monocyte Phenotype on 
Circulating Platelet-Monocyte Complexes in Overweight/Obese Persons 
 
MICHAEL M. LEVITT1, CONNOR GLASS1, CHERYL HASTON1, ANTHONY 
ANZALONE1, STEPHANIE TURNER1, MICHAEL G. FLYNN2, MELODY D. PHILLIPS1. 
 
1Exercise Physiology Laboratory; Kinesiology Dept.; Texas Christian University; Fort 
Worth, TX; 2Health & Human Performance Dept.; College of Charleston, Charleston, SC. 
 
Category:  Undergraduate 
 
Advisor / Mentor: Phillips, Melody D. (m.phillips@tcu.edu) 
 
ABSTRACT 
Elevated platelet-monocyte complexes (PMC) promote atherosclerosis and are associated with 
cardiovascular disease. It is unknown whether consistent physical activity (PA) decreases circulating 
PMCs.  Additionally, no one has determined the monocyte phenotype most associated with PMCs. 
PURPOSES:  1) to examine the influence of PA on PMCs and their association with inflammatory 
/prothrombotic markers such as C-reactive protein (CRP), L-selectin (LS), platelet factor 4 (PF4), von 
Willebrand Factor (vWF), and hemoglobin A1C (HbA1c) and 2) to determine the monocyte phenotype 
most likely to form PMCs.  METHODS: Thirty-one overweight/obese subjects (44±5yr, BMI 34.2±5 kgm2) 
were divided into two groups: sedentary (SED, n=17) and physically active (PA, n=14) based on physical 
activity logs.  SED participated in < 1 h of formal exercise while PA participated in moderate-high 
intensity exercise at least 3 h per week. Flow cytometry was used to identify PMCs on the monocyte 
phenotypes: classical (CD14+CD16-), intermediate (CD14+CD16+), and non-classical (CD14+CD16++).  
Platelets were identified using the marker CD42a. RESULTS:  Percentage of circulating PMCs and median 
fluorescence intensity of CD42a (MedFI; marker of platelet density per monocyte) were not different 
between groups; however, monocyte phenotype significantly impacted PMC percentage and MedFI where 
the lower the CD16 expression, the greater the adhesion of platelets. Classical monocytes (CD16-) had the 
highest % of PMC, etc. (Fig 1). HbA1c was greater (p=0.031) and LS (p=0.019) was lower in SED compared 
to PA (Fig. 2).  There were no significant associations between any blood marker and PMC percentage, but 
PF4 was correlated with percent of CD16 - (r= -0.482, p=0.031) and CD16+ (r= 0.473, p=0.035) monocytes.   
Fig. 1 
Phenotype 
Percent 
PMC  
MedFI 
 
Fig. 2 Dependent Variable PA SED p Value 
CD16- 32 ± 3.2a 184 ± 15abc 
 
VO2 max (ml∙kg-1∙min-1) 30 ±  6 27 ± 6 0.307 
CD16 + & ++ 25 ± 2.6a 159 ± 12ac 
 
HbA1c (%) 5.5 ±  0.9 5.8 ±  0.5 0.031* 
CD16+  28 ± 3.1a 163 ± 14b 
 
CRP (mg∙L-1) 8.1 ±  1.3 6.6 ±  1.3 0.347 
CD16++ 17 ± 2.1a 146 ± 11c 
 
L-Selectin (ng∙mL-1) 1087 ±  89  844 ±  48 0.019* 
Values with same letters are different from 
each other (p < 0.001) 
 
PF4 (μg∙mL-1) 1.52 ±  0.2 1.34 ±  0.2 0.584 
 
vWF (μg∙mL-1) 32 ±  3 24 ±  3 0.057 
CONCLUSIONS: The absence of a separation between groups in VO2max may partially explain the lack of 
a difference in PMCs between groups. Regarding our second aim, classical monocytes appear to be more 
involved in PMC formation than do CD16+ monocytes with CD16++ having the lowest percentage of cells 
with platelets adhered (PMC). This observation may be due to the shedding of adhesion molecules from 
platelets and monocytes during activation from classical (CD16-) to a more inflammatory state (ie. CD16+).   
